Payment overview · 2025
General Payments
$1,644.39
93 reported records · 25 companies
Healthcare provider profile · identity verified
Anthony Dewayne Davis, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LINDALE, TX · NPI 1962446898
Verified facts
What the public records show
CMS Open Payments records show Anthony Dewayne Davis, M.D. received $1,644.39 in general payments during 2025 across 93 reported records.
Amgen Inc. accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 509 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $213.11 | 13.0% | 21 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $183.06 | 11.1% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $168.21 | 10.2% | 12 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $154.33 | 9.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $135.53 | 8.2% | 9 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $93.28 | 5.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $93.02 | 5.7% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $80.69 | 4.9% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $73.84 | 4.5% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $51.90 | 3.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.51 | 2.8% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $45.40 | 2.8% | 2 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $39.81 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.02 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $30.26 | 1.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $28.77 | 1.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $28.52 | 1.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.96 | 1.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.06 | 1.2% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $19.28 | 1.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $18.84 | 1.1% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $17.34 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 1.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.85 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.62 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,644.39 | 93 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $177.21 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $168.21 | 12 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $156.61 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $154.33 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $143.45 | 16 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $135.53 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $128.99 | 15 | 2025 |
Source payment records
|
|||||
| THINPREP 2000 PROCESSOR Normalized: thinprep 2000 processor |
Device | Hologic Sales and Service, LLC | $93.28 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $76.24 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $73.84 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $69.66 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $60.54 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.08 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.51 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.51 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $45.40 | 2 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $39.81 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $30.26 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $28.77 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.96 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $21.34 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $20.06 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $18.84 | 1 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $17.34 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $5.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 509 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 92 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 54 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 129 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 30 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
54 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
129 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
509 | 71 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 753 | 198 |
| Amlodipine Besylate | Amlodipine Besylate | 541 | 134 |
| Atorvastatin Calcium | Atorvastatin Calcium | 532 | 138 |
| Eliquis | Apixaban | 509 | 71 |
| Gabapentin | Gabapentin | 495 | 110 |
| Losartan Potassium | Losartan Potassium | 436 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 420 | 127 |
| Ezetimibe | Ezetimibe | 418 | 127 |
| Lisinopril | Lisinopril | 371 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 360 | 106 |
| Metformin Hcl | Metformin Hcl | 329 | 84 |
| Potassium Chloride | Potassium Chloride | 324 | 89 |
| Omeprazole | Omeprazole | 319 | 87 |
| Duloxetine Hcl | Duloxetine Hcl | 310 | 71 |
| Furosemide | Furosemide | 307 | 88 |
| Trazodone Hcl | Trazodone Hcl | 267 | 65 |
| Tramadol Hcl | Tramadol Hcl | 257 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 241 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 70 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 48 |
| Donepezil Hcl | Donepezil Hcl | 215 | 66 |
| Carvedilol | Carvedilol | 209 | 56 |
| Alprazolam | Alprazolam | 207 | 42 |
| Simvastatin | Simvastatin | 184 | 58 |
| Hydrochlorothiazide | Hydrochlorothiazide | 176 | 55 |
| Sertraline Hcl | Sertraline Hcl | 172 | 36 |
| Montelukast Sodium | Montelukast Sodium | 169 | 42 |
| Celecoxib | Celecoxib | 158 | 45 |
| Spironolactone | Spironolactone | 155 | 42 |
| Buspirone Hcl | Buspirone Hcl | 142 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 139 | 44 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 129 | 44 |
| Ozempic | Semaglutide | 129 | 22 |
| Allopurinol | Allopurinol | 127 | 42 |
| Azithromycin | Azithromycin | 119 | 97 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 33 |
| Famotidine | Famotidine | 114 | 38 |
| Meloxicam | Meloxicam | 109 | 40 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 106 | 58 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | 30 |
| Lorazepam | Lorazepam | 98 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 94 | 14 |
| Glimepiride | Glimepiride | 92 | 26 |
| Jardiance | Empagliflozin | 92 | 19 |
| Pregabalin | Pregabalin | 92 | 11 |
| Atenolol | Atenolol | 91 | 20 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 90 | 26 |
| Clonazepam | Clonazepam | 90 | 15 |
| Xarelto | Rivaroxaban | 87 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 21 |
| Bumetanide | Bumetanide | 85 | 18 |
| Metformin Hcl Er | Metformin Hcl | 85 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 80 | 49 |
| Eszopiclone | Eszopiclone | 77 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 76 | 60 |
| Prednisone | Prednisone | 75 | 41 |
| Testosterone Cypionate | Testosterone Cypionate | 75 | 29 |
| Finasteride | Finasteride | 72 | 20 |
| Cephalexin | Cephalexin | 71 | 44 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 15 |
| Memantine Hcl | Memantine Hcl | 71 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 70 | 52 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 20 |
| Synthroid | Levothyroxine Sodium | 69 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 26 |
| Temazepam | Temazepam | 65 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 61 | 23 |
| Divalproex Sodium | Divalproex Sodium | 61 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 16 |
| Progesterone | Progesterone, Micronized | 60 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 23 |
| Ramipril | Ramipril | 58 | 14 |
| Bupropion Xl | Bupropion Hcl | 57 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 57 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 55 | 19 |
| Levetiracetam | Levetiracetam | 55 | 13 |
| Mounjaro | Tirzepatide | 54 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | 21 |
| Mirtazapine | Mirtazapine | 52 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 11 |
| Myrbetriq | Mirabegron | 50 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 41 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 49 | 12 |
| Fluconazole | Fluconazole | 48 | 41 |
| Glipizide | Glipizide | 48 | 13 |
| Kapspargo Sprinkle | Metoprolol Succinate | 48 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 47 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 47 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | 18 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 43 | suppressed |
| Methocarbamol | Methocarbamol | 43 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 40 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Np Thyroid | Thyroid,pork | 34 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 33 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | 14 |
| Colchicine | Colchicine | 31 | 18 |
| Levofloxacin | Levofloxacin | 31 | 19 |
| Midodrine Hcl | Midodrine Hcl | 31 | 12 |
| Nystatin | Nystatin | 31 | 17 |
| Ondansetron Odt | Ondansetron | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Estradiol | Estradiol | 30 | 12 |
| Methylprednisolone | Methylprednisolone | 30 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Budesonide | Budesonide | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 21 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Glucagon Emergency Kit | Glucagon | 22 | 20 |
| Admelog Solostar | Insulin Lispro | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 17 |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Metolazone | Metolazone | 19 | suppressed |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 12 |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Olanzapine | Olanzapine | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Nystop | Nystatin | 16 | 12 |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 15 | suppressed |
| Repatha Syringe | Evolocumab | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Xifaxan | Rifaximin | 15 | suppressed |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lubiprostone | Lubiprostone | 13 | suppressed |
| Mesalamine Er | Mesalamine | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Nyamyc | Nystatin | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Roflumilast | Roflumilast | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Flavoxate Hcl | Flavoxate Hcl | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Meropenem | Meropenem | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Sotalol Af | Sotalol Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,644.39 · 93 records | Amgen Inc. | CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, GEMTESA, INSPIRE, JARDIANCE, JATENZO, Kerendia, Korlym, LEQVIO, MOUNJARO, NEXLETOL, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, REPATHA, REXULTI, Rybelsus, Symbravo, THINPREP 2000 PROCESSOR, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, VYEPTI, WaveWriter Alpha Prime 16, Wegovy, XYOSTED, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error